Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Radiopharm Theranostics - Half Yearly Report and Accounts (ASX:RAD)

To view the report, download the attached PDF.

Radiopharm Theranostics - Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301 (ASX:RAD)

-- First Pancreatic Cancer participant dosed at the Montefiore Medical Center, New York, USA -- Phase I study of 9 participants is designed to assess the safety and dosimetry of RAD 301 -- A total...read more

Radiopharm Theranostics - Pilot Study Validates RAD Terbium-161 Radiotherapeutics (ASX:RAD)

-- Publication of first head-to-head data shows superior Therapeutic Index with Tb161 vs Lu177 in 6 metastatic castration-resistant prostate cancer patients. -- This Pilot study validates Radiophar...read more

Radiopharm receives $1.9M advance on FY24 R&D tax incentive (ASX:RAD)

Sydney, Australia – 21 February 2024 – Radiopharm Theranostics Limited (ASX:RAD), a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeuti...read more

Radiopharm Theranostics - Share Facility Agreement of up to A$12.5m addendum (ASX:RAD)

Further to Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company) announcement earlier today, the issue of shares under the Share Subscription Agreement is amended as below and attached. ...read more

Radiopharm Theranostics secures Share Facility Agreement of up to A$12.5m (ASX:RAD)

-- Up to A$12.5 million investment by US institutional investor, Lind Partners. -- Under a Share Subscription Agreement, RAD will receive A$1.2 million, with up to a further A$11.3 million in fundi...read more

Radiopharm Theranostics - RAD 502 can halt tumour progression and prolong survival (ASX:RAD)

Study by David Ulmert and colleagues demonstrated that non-invasive clinical imaging and targeted radioimmunotherapy with DUNP19 (RAD 502) can halt tumor progression and prolong survival in var...read more

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

-- Phase 1 clinical trial initiated (RAD204) for PDL1-positive non-small cell lung cancer and second site announced -- Phase 1 clinical trial initiated in New York to assess 68Ga-Trivehexin's (...read more

Radiopharm Theranostics - Investor Presentation (ASX:RAD)

To view the presentation, download the attached PDF.

Radiopharm Theranostics - Placement of Entitlement Offer Shortfall (ASX:RAD)

On 31 October 2023, Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company) announced the details of a non-renounceable entitlement offer (Entitlement Offer) to raise approximate...read more

Radiopharm Theranostics - 2nd Australian site for Nanomab-PDL-1 Phase 1 trial (ASX:RAD)

-- Ethics Committee approval received from Hollywood Private Hospital in Perth, WA -- Patient recruitment to commence shortly -- Phase 1 study in 21 patients designed to evaluate the safety and ef...read more

Radiopharm Theranostics - Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan (ASX:RAD)

-- Successful Site Initiation at Princess Alexandra Hospital, Brisbane for RAD 204 (PDL-1 nanobody) therapeutic Phase 1 trial -- Phase 1 First-In-Human study in 21 patients designed to evaluate saf...read more

Radiopharm Theranostics - Completion of Entitlement Offer (ASX:RAD)

Radiopharm receives $4.85M R&D tax incentive (ASX:RAD)

Sydney, Australia – 21 November 2023 – Radiopharm Theranostics Limited (ASX:RAD), a developer of a world class platform of radiopharmaceutical products for both diagnostic and thera...read more

Radiopharm Theranostics - Entitlement Offer Documents (ASX:RAD)

Sydney, Australia – 8 November 2023 – Radiopharm Theranostics (ASX:RAD), a developer of a worldclass platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is...read more

Viewing: 1 - 15 of 104 Previous | Next